Key result
Polyvascular disease was independently associated with a higher risk of 1-year all-cause death compared to acute myocardial infarction alone.
Why the study?
The impact of polyvascular disease in patients with acute myocardial infarction in the contemporary percutaneous coronary intervention era required investigation.
Does the presence of polyvascular disease increase the risk of all-cause death, MACE, and major bleeding in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention?
Observational (n=3,411)
Yes
Does the presence of polyvascular disease increase the risk of all-cause death, MACE, and major bleeding in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In patients with acute myocardial infarction undergoing contemporary PCI, the presence of polyvascular disease is independently associated with a significantly higher risk of 1-year all-cause mortality, MACE, and major bleeding.
BACKGROUND: This post hoc subanalysis aimed to investigate the impact of polyvascular disease (PolyVD) in patients with acute myocardial infarction (AMI) in the contemporary era of percutaneous coronary intervention (PCI). METHODS AND RESULTS: The Japan Acute Myocardial Infarction Registry (JAMIR), a multicenter prospective registry, enrolled 3,411 patients with AMI between December 2015 and May 2017. Patients were classified according to complications of a prior stroke and/or peripheral artery disease into an AMI-only group (involvement of 1 vascular bed [1-bed group]; n=2,980), PolyVD with one of the complications (2-bed group; n=383), and PolyVD with both complications (3-bed group; n=48). The primary endpoint was all-cause death. Secondary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and major bleeding. In the 1-, 2-, and 3-bed groups, the cumulative incidence of all-cause death was 6.8%, 17.5%, and 23.7%, respectively (P<0.001); that of MACE was 7.4%, 16.4%, and 33.8% (P<0.001), respectively; and that of major bleeding was 4.8%, 10.0%, and 13.9% (P<0.001), respectively. PolyVD was independently associated with all-cause death (hazard ratio [HR] 2.21; 95% confidence interval [CI], 1.48-3.29), MACE (HR 2.07; 95% CI 1.40-3.07), and major bleeding (HR 1.68; 95% CI 1.04-2.71). CONCLUSIONS: PolyVD was significantly associated with worse outcomes, including thrombotic and bleeding events, in the contemporary era of PCI in AMI patients.
No takes yet. Share an insight, caveat, or question.
Arai et al. (2023) conducted an observational in Acute Myocardial Infarction (n=3,411). Polyvascular disease vs. Acute myocardial infarction only (1 vascular bed) was evaluated on All-cause death within 1 year (HR 2.21, 95% CI 1.48-3.29, p=<0.001). Polyvascular disease was independently associated with a higher risk of 1-year all-cause death compared to acute myocardial infarction alone.
Synapse has enriched 10 related papers. Consider them for comparative context: